Semaglutide

People run it for two things: weight loss and blood-sugar control. The standout reported effect is heavy appetite suppression and a sharp drop in “food noise” — the constant background pull toward eating. It’s the rare peptide here with large Phase-3 trials behind the exact uses people run it for, including a roughly 15% average body-weight loss at ~68 weeks in non-diabetic adults.

Its identity is the one-receptor end of the ladder the community recites constantly: semaglutide hits one receptor (GLP-1), tirzepatide two, retatrutide three. Being single-receptor is why it’s both gentler and less powerful than what came after — it’s the baseline the others were built to beat. The other defining trait is that it’s once-weekly: a long half-life means one shot covers a week, which is a large part of why it broke through where older daily GLP-1 drugs didn’t. Beyond weight, the large cardiovascular trials are part of its reputation — it’s one of the few compounds on this site with hard-outcome human data, not just surrogate numbers.

A GLP-1 receptor agonist: it mimics the gut hormone GLP-1, which the body releases after eating. Activating that receptor does several things at once — it signals the brain’s appetite centers toward fullness (the “food noise” drop people describe), slows gastric emptying so food sits longer and you feel fuller for longer, and stimulates glucose-dependent insulin release while blunting glucagon, which is what drives the glycemic-control side. The slowed gastric emptying is also the direct source of the GI side effects. It’s a single receptor — no GIP, no glucagon activation — which is exactly what separates it from the dual and triple agonists.

The profile is dominated by GI effects, and they’re common: nausea above all, plus vomiting, diarrhea, constipation, and reflux. These are usually worst right after a dose increase and fade as the gut adapts — which is the entire reason for the slow titration. Beyond the gut, the most-raised concern in the community isn’t a classic side effect but muscle loss during rapid weight loss: trial body-composition data show a meaningful share of the weight lost is lean mass, which is why protein intake and resistance training dominate the conversation, exactly as with the stronger agonists. Because there’s an approved regulatory form, the serious cautions are well-characterized: a boxed warning for thyroid C-cell tumors (rodent data; avoid with personal/family history of medullary thyroid carcinoma or MEN2), pancreatitis, and gallbladder issues that track with fast weight loss. There are also reports of rapid muscle and weight regain after stopping if diet and training don’t hold.

In practice it’s run standalone — there’s no community peptide-stacking protocol for it. When people say “stack” around semaglutide they almost always mean the support scaffolding, not another compound: high protein and resistance training to protect muscle during the loss, plus electrolytes and micronutrients to offset reduced intake. The other recurring move isn’t a stack at all but a swap — people who plateau or want more often step up to a dual or triple agonist rather than adding to semaglutide.